These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11255561)

  • 81. [Indications for hormone replacement therapy].
    Birkhäuser MH
    Ther Umsch; 2000 Oct; 57(10):635-42. PubMed ID: 11081375
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
    Gennari L
    Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.
    Thiebaud D; Secrest RJ
    Reprod Fertil Dev; 2001; 13(4):331-6. PubMed ID: 11800172
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Raloxifene, tamoxifen and vascular tone.
    Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
    Jordan VC
    J Natl Cancer Inst; 2001 Jan; 93(1):2-4. PubMed ID: 11136828
    [No Abstract]   [Full Text] [Related]  

  • 87. Raloxifene hydrochloride.
    Snyder KR; Sparano N; Malinowski JM
    Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Selective oestrogen receptor modulators in desmoid tumours.
    Picariello L; Tonelli F; Brandi ML
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1457-68. PubMed ID: 15500393
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of SERMs on the uterus and menopausal symptoms.
    Dören M
    J Endocrinol Invest; 1999 Sep; 22(8):625-35. PubMed ID: 10532250
    [No Abstract]   [Full Text] [Related]  

  • 93. Raloxifene: a new choice for treating and preventing osteoporosis.
    Licata AA; Ciaccia AV; Wong M; Draper MW
    Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors.
    Walsh BW
    Ann N Y Acad Sci; 2001 Dec; 949():163-7. PubMed ID: 11795349
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women.
    Goldstein SR
    Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1479-84. PubMed ID: 9855584
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Chemoprevention of breast cancer with selective oestrogen-receptor modulators.
    Jordan VC
    Nat Rev Cancer; 2007 Jan; 7(1):46-53. PubMed ID: 17186017
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tolerability profile of SERMs.
    Agnusdei D; Iori N
    J Endocrinol Invest; 1999 Sep; 22(8):641-5. PubMed ID: 10532252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.